by Respiratory tract infection occurs when bacteria or viruses infect the airways and lungs. Common respiratory tract infections include the common cold, sinusitis, pharyngitis, bronchitis, and pneumonia. Increased urbanization and pollution levels have led to rising airborne diseases and respiratory ailments. Symptoms include cough, runny or stuffy nose, sore throat, fever, and shortness of breath.
Treatment of respiratory tract infections involves medication to relieve symptoms and speed up recovery. Antibiotics are prescribed for bacterial infections while antihistamines and decongestants help provide relief from allergies and nasal congestion. Home remedies involving rest, increased fluid intake and steam inhalation also aid recovery.
The global respiratory tract infection treatment market is estimated to be valued at US$ 89.57 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing prevalence of respiratory diseases: Rising air pollution levels and growing number of smokers have been raising the incidence of respiratory ailments like asthma and COPD globally. Pollutants exacerbate respiratory symptoms and reduce lung function over time. As highlighted in the heading, increasing prevalence of respiratory diseases across urban populations is expected to drive higher demand for drugs to treat associated infections.
Air pollutants act as irritants and allergens that damage lung tissue and lower the body’s defenses against invading pathogens. This makes people more susceptible to respiratory infections. Growing pollution levels thus represent a key driver propelling the respiratory tract infection treatment market.
Segment Analysis
The Respiratory Tract Infection Treatment Market Analysis is segmented based on disease type, drug class and distribution channel. The antibiotic drugs dominate the market holding around 60% share owing to large patient pool suffering from bacterial infections. The disease segment is further divided into upper respiratory tract infection and lower respiratory tract infection. Upper respiratory tract infection segment holds the major share due to high prevalence of common cold worldwide.
PEST Analysis
Political: Governments across countries are focusing on expanding health coverages for treatment of respiratory infections which is positively impacting the market growth.
Economic: Rising per capita income is enabling people to spend more on healthcare, thereby supporting market expansion.
Social: Growing awareness about availability of effective drugs is increasing the demand for respiratory tract infection treatment drugs.
Technological: Advancements in drug delivery systems and development of combination drugs are propelling the market growth.
Key Takeaways
The global respiratory tract infection treatment market is expected to witness high growth at a CAGR of 7.1% during the forecast period of 2023 to 2030.
Regional analysis shows that North America leads the market and Asia Pacific will emerge as the fastest growing market over the coming years.
Abbott Laboratories, AstraZeneca, Plc, Abbvie Inc., Boehringer Ingelheim GmbH, Cipla Pharmaceutical Company, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Novartis AG, F. Hoffman La Roche Ltd, Sanofi, and Teva Pharmaceutical Industries Ltd are the key players operating in the respiratory tract infection treatment market. Key players are focusing on new product launches and acquisition strategies to expand their market share. However, high treatment cost and risk of antibiotic resistance may hamper the market growth over the forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
